| Literature DB >> 33207632 |
Mohd Heikal Mohd Yunus1,2, Abid Nordin1, Haziq Kamal1.
Abstract
Osteoarthritis (OA) is the most well-known degenerative disease among the geriatric and is a main cause of significant disability in daily living. It has a multifactorial etiology and is characterized by pathological changes in the knee joint structure including cartilage erosion, synovial inflammation, and subchondral sclerosis with osteophyte formation. To date, no efficient treatment is capable of altering the pathological progression of OA, and current therapy is broadly divided into pharmacological and nonpharmacological measures prior to surgical intervention. In this review, the significant risk factors and mediators, such as cytokines, proteolytic enzymes, and nitric oxide, that trigger the loss of the normal homeostasis and structural changes in the articular cartilage during the progression of OA are described. As the understanding of the mechanisms underlying OA improves, treatments are being developed that target specific mediators thought to promote the cartilage destruction that results from imbalanced catabolic and anabolic activity in the joint.Entities:
Keywords: cytokines; osteoarthritis; pathogenesis; proteolytic enzymes
Mesh:
Substances:
Year: 2020 PMID: 33207632 PMCID: PMC7696673 DOI: 10.3390/medicina56110614
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Stages of pain in osteoarthritis (OA).
| Early stage |
| Middle stage (mild-moderate) |
| Advanced stages |
Potential mechanisms in the event of OA.
| Inflammatory Mediators | Description of Mechanism |
|---|---|
| Cytokines and Chemokines | IL-1, IL-6, IL-8: autocrine/paracrine agent; induce chondrocytes to produce proteases, nitric oxide, and eicosanoids such as prostaglandins and leukotrienes [ inhibit matrix synthesis, and promote cellular apoptosis [ induce the synthesis of matrix metalloproteinases (MMP 1, MMP 3, MMP 13) TNFα, IL-6 and IL-8 to drives the cartilage matrix breakdown [ decreases the synthesis of, such as proteoglycans, aggrecan, and type II collagen [ secreted by senescent cells, responsible for the loss of the cartilage extracellular matrix (ECM) the capability to maintain and repair [ |
| Proteases | MMP-1, -3, -13 and degradation of collagenous framework and extracellular matrix [ activator of other collagenases (MMPs 1, 8, and 13) that implicated in type II collagen degradation [ most an important role during OA pathogenesis [ secreted by hypertrophic chondrocytes in OA cartilage [ degrades type II collagen as the main articular ECM [ |
| iNOS (NO) |
induce inhibition the synthesis of both proteoglycans and collagen [ upregulate the synthesis of matrix metalloproteinases [ induce chondrocyte apoptosis; reduced the survival of cells and inhibited mitochondrial respiratory chain function and ATP synthesis [ |
| COX-2 (PGE2) |
suppress the production of proteoglycans, enhances the degradations of both aggrecan and type II collagen [ involves inflammation, apoptosis, angiogenesis [ enhances the effects of IL-6, MMP-3 and MMP-13 [ |
| PAR-2 |
induces pain and osteophytes formation [ induces production of IL6, IL8, MMPs (MMP1, MMP13) and PGE2 to enhance inflammatory responses [ |
Figure 1Inflammatory mediators in OA.